J H Antin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
  2. ncbi request reprint A 41-year-old woman with chronic myelogenous leukemia
    Joseph H Antin
    Massachusetts General Hospital, Boston, Mass, USA
    JAMA 290:1083-90. 2003
  3. ncbi request reprint Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease
    Joseph H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 10:655-68. 2004
  4. ncbi request reprint Immune reconstitution: the major barrier to successful stem cell transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 11:43-5. 2005
  5. ncbi request reprint Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
    Joseph H Antin
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:3479-82. 2002
  6. ncbi request reprint Stem cell transplantation-harnessing of graft-versus-malignancy
    Joseph H Antin
    Stem Cell Transplantation Program, Dana Faber Cancer Institute, Division of Medical Oncology and Hematology, Brigham, MA, USA
    Curr Opin Hematol 10:440-4. 2003
  7. ncbi request reprint Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood an
    J H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:473-85. 2001
  8. ncbi request reprint Donor leukocyte infusions and graft-versus-malignancy
    Joseph H Antin
    Medical Oncology Stem Cell Transplantation Program, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Apher 20:113-6. 2005
  9. ncbi request reprint Recovery after stem-cell transplantation for hematologic diseases
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:242-52. 2001
  10. pmc Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Edwin P Alyea
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:920-6. 2008

Research Grants

Collaborators

Detail Information

Publications103 found, 100 shown here

  1. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  2. ncbi request reprint A 41-year-old woman with chronic myelogenous leukemia
    Joseph H Antin
    Massachusetts General Hospital, Boston, Mass, USA
    JAMA 290:1083-90. 2003
  3. ncbi request reprint Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease
    Joseph H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 10:655-68. 2004
  4. ncbi request reprint Immune reconstitution: the major barrier to successful stem cell transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 11:43-5. 2005
  5. ncbi request reprint Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
    Joseph H Antin
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:3479-82. 2002
    ..We conclude that blockade of IL-1 using IL-1Ra during conditioning and 10 days immediately after transplantation is not sufficient to reduce GVHD or toxicity or to improve survival...
  6. ncbi request reprint Stem cell transplantation-harnessing of graft-versus-malignancy
    Joseph H Antin
    Stem Cell Transplantation Program, Dana Faber Cancer Institute, Division of Medical Oncology and Hematology, Brigham, MA, USA
    Curr Opin Hematol 10:440-4. 2003
    ..The graft-versus-malignancy effect, that is, the recognition of residual cancer cells by the T cells of the donor, is a critical component of the transplantation process...
  7. ncbi request reprint Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood an
    J H Antin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:473-85. 2001
    ..Interventions to enhance donor engraftment must be considered on a disease-specific basis in relation to concurrent GVHD and, ultimately, clinical rationale...
  8. ncbi request reprint Donor leukocyte infusions and graft-versus-malignancy
    Joseph H Antin
    Medical Oncology Stem Cell Transplantation Program, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Apher 20:113-6. 2005
  9. ncbi request reprint Recovery after stem-cell transplantation for hematologic diseases
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:242-52. 2001
    ....
  10. pmc Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Edwin P Alyea
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:920-6. 2008
    ....
  11. ncbi request reprint HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
    V T Ho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:845-50. 2006
    ..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST...
  12. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  13. pmc Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
    J R Brown
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Leukemia 27:362-9. 2013
    ..0001). We conclude that RIC HSCT for CLL in the current era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should be considered early in the disease course of relapsed high-risk CLL patients...
  14. pmc (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma
    K E Abou-Nassar
    Lymphoma Program, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Bone Marrow Transplant 46:1503-9. 2011
    ..Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies...
  15. pmc Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis
    C Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 46:659-67. 2011
    ..In summary, sirolimus and tacrolimus provide excellent GVHD prophylaxis in DUCBT, and this regimen is associated with low NRM after DUCBT...
  16. pmc A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome
    E D Jacobsen
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1608-13. 2011
    ..The prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome...
  17. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  18. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
    ..The omission of mini-MTX from the Tac/Sir GVHD prophylaxis regimen appears to have no adverse effect on the development of aGVHD...
  19. ncbi request reprint Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
    J H Antin
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115
    Blood 84:1342-8. 1994
    ..Inhibition of IL-1 activity with IL-1Ra is safe and has demonstrable efficacy in acute GVHD that failed to respond to conventional treatment. These data provide further evidence that IL-1 is a mediator of GVHD...
  20. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007
    ..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures...
  21. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
    ..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL...
  22. ncbi request reprint CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
    R J Soiffer
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1152-9. 2001
    ..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...
  23. ncbi request reprint Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1047-55. 2006
    ..These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation...
  24. pmc Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:3108-14. 2007
    ..Differences between MRD and URD cohorts are not evident when effective GVHD prophylaxis is used...
  25. ncbi request reprint Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 10:328-36. 2004
    ..Mucositis was modest, engraftment was prompt, and transplant-related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be tested in randomized trials against the current standard of care...
  26. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
    ..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
  27. pmc Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy
    P Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Bone Marrow Transplant 45:1611-7. 2010
    ..A significant proportion of women with tAML/MDS after breast cancer treatment experience DFS after HSCT, similar to that of patients with de novo MDS or AML. This justifies consideration of HSCT for selected patients in this setting...
  28. ncbi request reprint Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation
    V T Ho
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:223-9. 2001
    ..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs...
  29. pmc Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 112:4425-31. 2008
    ..Sirolimus-based GVHD prophylaxis without methotrexate is associated with the greatest overall survival. Myeloablative doses of busulfan should not be used with sirolimus-based immunosuppression...
  30. ncbi request reprint Predicting costs of stem-cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 18:64-71. 2000
    ..We sought (1) to determine whether obtaining baseline information enabled identification of patients whose treatments would be the most costly and (2) to estimate inpatient costs for managing specific transplantation complications...
  31. pmc Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation
    R L Haspel
    Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
    Bone Marrow Transplant 41:523-9. 2008
    ....
  32. ncbi request reprint Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis
    C Cutler
    Division of Hematologic Oncology, Dana Farber Cancer Institute, and Harvard School of Public Health, Boston, MA 02115, USA
    J Clin Oncol 19:3685-91. 2001
    ..We performed a meta-analysis of all trials comparing the incidence of acute and chronic GVHD after PBSCT and BMT reported as of June, 2000. Secondary analyses examined relapse rates after the two procedures...
  33. ncbi request reprint Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease
    Daniel J DeAngelo
    Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:5065-71. 2004
    ..Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses...
  34. ncbi request reprint Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:383-8. 2005
    ..Less toxic GVHD prophylaxis regimens without methotrexate may have a significant effect on patient quality of life, patient outcomes, and economic outcomes associated with allogeneic stem cell transplantation...
  35. ncbi request reprint A comparison of related and unrelated marrow donors
    G Chang
    Division of Psychiatry, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Psychosom Med 60:163-7. 1998
    ..The purpose of this investigation is to test whether related bone marrow donors experience more distress from marrow donation than volunteer unrelated donors...
  36. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
    ..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD...
  37. ncbi request reprint Substance abuse and bone marrow transplant
    G Chang
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Drug Alcohol Abuse 23:301-8. 1997
    ..054) and by history of cigarette smoking (p = .07) were also identified. Lifetime substance abuse or dependence appears to have an adverse association with survival after bone marrow transplant when other clinical factors are equal...
  38. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
    ..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs...
  39. ncbi request reprint Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
    M J Vasconcelles
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 6:35-43. 2000
    ....
  40. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  41. ncbi request reprint Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:551-7. 2005
    ..A careful monitoring strategy for TMA should be used with a sirolimus-containing graft-versus-host disease prophylaxis regimen...
  42. pmc Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:655-64. 2007
    ....
  43. ncbi request reprint Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    Martha Wadleigh
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1578-82. 2003
    ..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
  44. pmc Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes
    H Mawardi
    Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
    Bone Marrow Transplant 46:884-91. 2011
    ..The observation that oral cancers were frequently multifocal and recurred locally suggests that these cancers may be more aggressive. Vigilant follow-up and coordination of care are critical...
  45. ncbi request reprint A survey of diagnosis, management, and grading of chronic GVHD
    Stephanie J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:32-9. 2002
    ..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD...
  46. pmc High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncolog, Dana Farber Cancer Institute and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:6107-14. 2007
    ..Thus, we tested whether BAFF correlated with chronic GVHD disease activity and time of onset after allogeneic hematopoietic stem cell transplantation (HSCT)...
  47. ncbi request reprint Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation
    Thomas S Lin
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Transplantation 74:49-54. 2002
    ..We sought to determine the effect of prior donor and patient CMV exposure on the incidence of CMV infection after TCD allogeneic HSCT...
  48. ncbi request reprint Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation
    C Cutler
    Dana Farber Cancer Institute, Boston MA 02115, USA
    Bone Marrow Transplant 34:471-6. 2004
    ....
  49. ncbi request reprint A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation
    J H Antin
    Department of Adult Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 29:373-7. 2002
    ..The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial...
  50. ncbi request reprint Peripheral blood stem cells for allogeneic transplantation: a review
    C Cutler
    Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Stem Cells 19:108-17. 2001
    ..It is possible that a stronger graft-versus-tumor effect may exist with PBSCs when compared with BM although the mechanisms leading to this effect are not clear...
  51. pmc Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3956-9. 2009
    ..Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation. This study was registered at http://www.clinicaltrials.gov as #NCT00369226...
  52. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009
    ....
  53. pmc Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS)
    Grace Chang
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Am J Drug Alcohol Abuse 36:1-6. 2010
    ..Patients' substance use problems are a particularly understudied aspect of psychosocial variables in cancer treatment...
  54. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  55. ncbi request reprint Phase I trial of parathyroid hormone to facilitate stem cell mobilization
    Karen K Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:838-43. 2007
    ..PTH was well tolerated at doses up to 100 microg in human cancer patients. The efficacy of PTH for mobilization of hematopoietic stem cells will need to be tested in a larger Phase II study...
  56. pmc Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 120:1479-93. 2010
    ..These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations...
  57. pmc Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation
    Yi Bin Chen
    Department of Hematology Oncology, Division of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 15:1066-76. 2009
    ....
  58. pmc A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:28-35. 2008
    ....
  59. pmc Mental status changes after hematopoietic stem cell transplantation
    Grace Chang
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:4625-35. 2009
    ..The objective of this study was to evaluate and compare neurocognitive changes in patients with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) after allogeneic HSCT or other therapies...
  60. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  61. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  62. ncbi request reprint Clinical practice. Long-term care after hematopoietic-cell transplantation in adults
    Joseph H Antin
    Adult Oncology Stem Cell Transplantation Program, Department of Adult Oncology, Dana Farber Cancer Institute, and Brigham and Women s Hospital, Boston 02115, USA
    N Engl J Med 347:36-42. 2002
  63. ncbi request reprint Development and validation of a scale to measure symptoms of chronic graft-versus-host disease
    Stephanie k Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:444-52. 2002
    ..The cGVHD symptom scale is a short, simple, and valid measure of cGVHD manifestations and can be used to follow complication-specific symptoms using patient self-administered questionnaires...
  64. pmc Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 301:2349-61. 2009
    ..Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML...
  65. ncbi request reprint Novel drugs for the prevention and treatment of acute GVHD
    Corey Cutler
    Harvard Medical School, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Curr Pharm Des 14:1962-73. 2008
    ..In this article, we will review the current standards for prevention and treatment of acute GVHD, and discuss novel drugs and therapeutics that hold promise for improved prevention and management of established acute GVHD...
  66. ncbi request reprint Allogeneic stem cell transplantation for aplastic anemia
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:505-16. 2007
    ..We then outline a framework for deciding which patients should be considered for upfront transplantation...
  67. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  68. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
    ..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting...
  69. ncbi request reprint Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome
    Grace Chang
    Department of Psychiatry, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 101:782-9. 2004
    ..The objective of this study was to evaluate psychosocial predictors of long-term survival and disease recurrence after patients underwent allogeneic HSCT for chronic myelogenous leukemia (CML)...
  70. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  71. pmc Donor-derived second hematologic malignancies after cord blood transplantation
    Karen K Ballen
    Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1025-31. 2010
    ..Second myelogenous malignancies of donor origin occur after double UCBT, suggesting that a search for donor origin should be performed in all patients with suspected relapse...
  72. pmc Evidence for ineffective erythropoiesis in severe sickle cell disease
    Catherine J Wu
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 106:3639-45. 2005
    ....
  73. ncbi request reprint Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation
    Joseph H Antin
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 11:213-22. 2005
    ..Pneumococcal conjugate vaccine is immunogenic in autoHCT patients and may be an effective strategy to prevent invasive disease after transplantation...
  74. pmc Rituximab for steroid-refractory chronic graft-versus-host disease
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 108:756-62. 2006
    ..We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00136396...
  75. ncbi request reprint Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 12:552-9. 2006
    ..Sirolimus and voriconazole may be safely coadministered if there is an empiric initial 90% sirolimus dose reduction combined with systematic monitoring of trough levels...
  76. ncbi request reprint Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
    Francisco M Marty
    Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
    Blood 102:2768-76. 2003
    ..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used...
  77. ncbi request reprint Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient
    Benjamin D Humphreys
    Harvard Medical School, Boston, MA 02115, USA
    Nat Clin Pract Nephrol 2:535-9; quiz 540. 2006
    ..After 5 days, she developed fatigue with progressive weight gain and edema, and 14 days after immunization she presented with anasarca and was found to have acute renal failure and nephrotic proteinuria...
  78. ncbi request reprint Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
    ..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation...
  79. ncbi request reprint Symptoms of pain and depression in related marrow donors: changes after transplant
    Grace Chang
    Department of Psychiatry, Brigham and Women s Hospital, Boston, MA 02115, USA
    Psychosomatics 44:59-64. 2003
    ..Approximately 6 months after marrow donation, related marrow donors whose recipients died had significantly higher Beck Depression Inventory scores than did donors whose related recipients were living...
  80. ncbi request reprint Predictors of 1-year survival assessed at the time of bone marrow transplantation
    Grace Chang
    Brigham and Women s Hospital, Boston, MA, USA
    Psychosomatics 45:378-85. 2004
    ..However, other clinical variables prior to transplant and once transplant occurred were found to predict survival...
  81. pmc Double unrelated reduced-intensity umbilical cord blood transplantation in adults
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:82-9. 2007
    ..Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen...
  82. ncbi request reprint Psychosocial function after hematopoietic stem cell transplantation
    Grace Chang
    Department of Psychiatry, Brigham and Women s Hospital Boston, MA 02115, USA
    Psychosomatics 46:34-40. 2005
    ..Time was the most important variable accounting for these changes...
  83. pmc Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
    L Li
    Department of Medicine, Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Blood Cancer J 4:e178. 2014
    ..These effects of the PGE2/Wnt/β-catenin axis may have significant implications for harnessing immunity in the context of UCBT, where impaired immune reconstitution is associated with late memory T-cell skewing...
  84. ncbi request reprint Discrepancies between patient and physician estimates for the success of stem cell transplantation
    S J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 285:1034-8. 2001
    ..Stem cell transplantation is associated with considerable morbidity and mortality. The extent to which patients and their physicians correctly estimate these risks is unknown...
  85. pmc Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes
    Yishai Ofran
    Division of Hematologic Malignancies, Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 16:1642-51. 2010
    ..Because relatively few mHAs are known, we developed a new approach to predict and subsequently validate candidate mHA...
  86. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
    ..These studies delineate specific abnormalities of B-cell homeostasis in patients with cGVHD and suggest that BAFF targeting agents may be useful in this disease...
  87. ncbi request reprint Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy
    Abba C Zubair
    Connell O Reilly Cell Manipulation Core Facility, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Transfusion 44:253-61. 2004
  88. pmc Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
    David B Miklos
    Department of Medical Oncology and Biostatistical Science, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    Blood 103:353-9. 2004
    ..These studies demonstrate that the immune response to mHA includes the generation of specific antibodies and suggests that the serologic response to these antigens may also be useful in the identification of new mHAs...
  89. ncbi request reprint Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:4337-43. 2002
    ..Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure...
  90. ncbi request reprint Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6
    W W Seeley
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neurology 69:156-65. 2007
    ..Clinical and laboratory features of the syndrome, however, have not been well characterized...
  91. ncbi request reprint Donor leukocyte infusions in myeloid malignancies: new strategies
    David L Porter
    University of Pennsylvania Medical Center, 16 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA
    Best Pract Res Clin Haematol 19:737-55. 2006
    ..Although many issues remain unsettled, the potential to harness the graft-versus-leukemia activity of allogeneic donor cells provides a powerful new paradigm for the immunotherapy of cancer...
  92. ncbi request reprint Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
    Daniel J Weisdorf
    University of Minnesota Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 99:1971-7. 2002
    ..Improvements in URD and MSD transplantation are still needed, and results of newer, nontransplantation therapies should be evaluated against the established curative potential of URD and MSD marrow transplantation...
  93. pmc Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) pros
    Jean Yves Cahn
    Department of Onco Hematology, Hopital Michallon, Centre Hospitalo Universitaire, INSERM EMI 353, 38700 Grenoble Cedex 9, France
    Blood 106:1495-500. 2005
    ..Validity of these results in populations receiving peripheral blood transplants or nonmyeloablative conditioning regimens remains to be tested...
  94. ncbi request reprint Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases
    Fausto R Loberiza
    Health Policy Institute and the Department of Medicine, Hematology and Oncology, Bone Marrow Transplantation Program, Medical College of Wisconsin, Milwaukee, WI 53224, USA
    J Clin Oncol 20:2118-26. 2002
    ..However, depression is not well studied in the setting of hematopoietic stem-cell transplantation (HSCT). We examined the association between depressive syndrome and survival after HSCT...
  95. ncbi request reprint Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation
    Edwin P Alyea
    Biol Blood Marrow Transplant 8:601-7. 2002
    ..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates...
  96. ncbi request reprint Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
    Hakumei Oh
    GVHD Immune Reconstitution Wroking Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milaukee, WI, USA
    Blood 105:1408-16. 2005
    ..04) and chronic (RR = 3.16; P = .002) GVHD. No differences in other clinical outcomes were noted. Our findings suggest that ethnicity may influence the risk for GVHD, though overall survival rates after transplantation remain similar...
  97. ncbi request reprint Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation
    Deborah C Molrine
    Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, MA 02130, USA
    Blood 101:831-6. 2003
    ..A 3-dose schedule of PCV7 vaccine at 3, 6, and 12 months is immunogenic in these patients regardless of donor immunization...
  98. ncbi request reprint Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
    Stephanie J Lee
    Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 100:406-14. 2002
    ..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression...
  99. pmc Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis
    Catherine J Wu
    Br J Haematol 139:504-7. 2007
  100. ncbi request reprint Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation
    Mark J DiNubile
    Division of Infectious Diseases, Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Camden, NJ, USA
    Blood 100:4367-71. 2002
    ..0007). These findings suggest that gelsolin levels shortly after allogeneic HSCT can predict the later development of fatal IPS. Gelsolin replacement in selected transplant patients may offer a novel strategy to prevent or reverse IPS...
  101. pmc HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR
    Richard F Schlenk
    University of Ulm, Ulm, Germany
    Biol Blood Marrow Transplant 14:187-96. 2008
    ..These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT...

Research Grants2

  1. Random Trial of CD8 T-Cell Depletion in PBSC Transplantation
    Joseph Antin; Fiscal Year: 2007
    ..End of abstract.) ..